Vectormune FP ILT

Authorised

This medicine is authorised for use in the European Union

fowlpox and avian infectious laryngotracheitis vaccine (live, recombinant)

MedicineVeterinaryAuthorised

Greek is available via eTranslation, the European Commission's machine translation service.

Translate to Greek | Important information about machine translation

Application under evaluation
CVMP opinion
European Commission decision

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website.

Product information

Vectormune FP ILT : EPAR - Product Information

English (EN) (81.49 KB - PDF)

Δημοσιεύθηκε για πρώτη φορά: 10/09/2021 Τελευταία ενημέρωση: 27/05/2024

Άλλες γλώσσες (25)

Vectormune FP ILT : EPAR - All authorised presentations

English (EN) (81.94 KB - PDF)

Δημοσιεύθηκε για πρώτη φορά: 10/09/2021 Τελευταία ενημέρωση: 27/05/2024

Άλλες γλώσσες (25)

Product details

Name of medicine: Vectormune FP ILT
Active substance: recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live
International non-proprietary name (INN) or common name: fowlpox and avian infectious laryngotracheitis vaccine (live, recombinant)

Pharmacotherapeutic group

Immunologicals for aves
Live viral vaccines
Domestic fowl

Authorisation details

EMA product number: EMEA/V/C/005482

Assessment history

Vectormune FP ILT : EPAR - Public assessment report

Adopted Reference Number: EMA/565679/2020

English (EN) (81.49 KB - PDF)

Δημοσιεύθηκε για πρώτη φορά: 10/09/2021 Τελευταία ενημέρωση: 27/05/2024

CVMP summary of positive opinion for Vectormune FP ILT

Adopted Reference Number: EMA/CVMP/505185/2020

English (EN) (132.19 KB - PDF)

Δημοσιεύθηκε για πρώτη φορά: 09/10/2020

News on Vectormune FP ILT

This page was last updated on 27/05/2024